医学
心肌梗塞
心力衰竭
干细胞
粒细胞集落刺激因子
骨髓干细胞
疾病
粒细胞
细胞疗法
干细胞疗法
重症监护医学
移植
心脏病学
内科学
生物信息学
生物
化疗
遗传学
作者
Domenico D’Amario,Antonio Maria Leone,Josip Anđelo Borovac,F. Cannata,Alessandra Siracusano,Giampaolo Niccoli,Filippo Crea
标识
DOI:10.1016/j.phrs.2017.06.001
摘要
Heart failure and acute myocardial infarction are conditions that are associated with high morbidity and mortality. Significant dysfunction of the heart muscle can occur as the consequence of end-stage chronic cardiovascular diseases or acute ischemic events that are marked by large infarction area and significant tissue necrosis. Despite the remarkable improvement of conventional treatments, a substantial proportion of patients still develops severe heart failure that can only be resolved by heart transplantation or mechanical device implantation. Therefore, novel approaches based on stem-cell therapy can directly modify the disease process and alter its prognosis. The ability of the stem-cells to modify and repair the injured myocardium is a challenging but intriguing concept that can potentially replace expensive and invasive methods of treatment that are associated with increased risks and significant financial costs. In that sense, granulocyte colony-stimulating factor (G-CSF) seems as an attractive treatment approach. Based on the series of pre-clinical experiments and a limited amount of clinical data, it was demonstrated that G-CSF agents possess the ability to mobilize stem-cells from bone marrow and induce their differentiation into cardiomyocytes or endothelial cells when brought into contact with injured regions of the myocardium. However, clinical benefits of G-CSF use in damaged myocardium remain unclear and are the topic of expert discussion. The main goal of this review is to present relevant and up-to-date evidence on G-CSF therapy use in pre-clinical models and in humans and to provide a rationale for its potential clinical applications in the future.
科研通智能强力驱动
Strongly Powered by AbleSci AI